Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Related Questions
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Is there evidence supporting the role of SBRT in the management of oligometastatic stage IV NSCLC?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
